GI
FDMT icon

GAMMA Investing’s 4D Molecular Therapeutics FDMT Stock Holding History

GAMMA Investing’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.1K Buy
1,543
+209
+16% +$2.72K ﹤0.01% 2890
2026
Q2 		$17.7K Buy
1,334
+147
+12% +$1.43K ﹤0.01% 2899
2026
Q1 		$11.1K Sell
1,187
-464
-28% -$4.04K ﹤0.01% 3017
2025
Q4 		$12.4K Buy
1,651
+501
+44% +$5.08K ﹤0.01% 2872
2025
Q3 		$9.99K Buy
1,150
+1,142
+14,275% +$6.83K ﹤0.01% 2877
2025
Q2 		$30 Hold
8
– – ﹤0.01% 3766
2025
Q1 		$26 Hold
8
– – ﹤0.01% 3788
2024
Q4 		$45 Sell
8
-32
-80% -$251 ﹤0.01% 3766
2024
Q3 		$432 Sell
40
-1
-2% -$17 ﹤0.01% 3413
2024
Q2 		$861 Sell
41
-36
-47% -$903 ﹤0.01% 3095
2024
Q1 		$2.45K Buy
77
+21
+38% +$536 ﹤0.01% 2691
2023
Q4 		$966 Buy
+56
New +$737 ﹤0.01% 2797

Other funds holding FDMT

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's FDMT Position: Q3 2026 in Review

GAMMA Investing increased its 4D Molecular Therapeutics (FDMT) stake by 16% in Q3 2026, buying an estimated $2.72K and bringing the position to 1,543 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

GAMMA Investing first reported a position in FDMT in Q4 2023 and has held it in 12 quarters since. 5 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • GAMMA Investing held 1,543 shares of 4D Molecular Therapeutics worth $22.1K as of Q3 2026.
  • GAMMA Investing bought 209 4D Molecular Therapeutics shares in Q3 2026, an estimated $2.72K.
  • 4D Molecular Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2890 holding.
  • GAMMA Investing first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 5 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.